Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events grade 3 to 5 Range of · patients with non‐muscle invasive bladder cancer

Gemcitabine showed no clear difference in grade III–V adverse events compared with saline (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 1.26 [0.58, 2.75]
2 studies · 668 participants
Low

Adverse events: grade 1 to 2 · patients with non‐muscle invasive bladder cancer

Gemcitabine showed no clear difference in grade I or II adverse events compared with saline (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 1.13 [0.87, 1.45]
2 studies · 668 participants
Low